BRCA1 and neoplasm: Our study shows that for cancer centres that use a tumour-first BRCA1/2 testing approach using the myChoice® CDx, around 5–10% of germline BRCA1/2 pathogenic variants may not be reported, all of which are likely to be pathogenic large rearrangements.